BeiGene, Novartis in pact to develop tislelizumab for cancer settings

BeiGene, Novartis in pact to develop tislelizumab for cancer settings

Submitted by admin on January 11, 2021 - 6:56pm
Source: 
Seeking Alpha
News Tags: 
Novartis
BeiGene
tiselizumab
cancer
drug development
Headline: 
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
snippet: 

BeiGene (NASDAQ:BGNE) has announced a collaboration and license agreement with Novartis Pharma (NYSE:NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab.

Do Not Allow Advertisers to Use My Personal information